As Jay Bhattacharya steps into a temporary leadership role at the CDC while maintaining his position as director of the NIH, staff members at the NIH raise concerns that his focus may be divided at a critical time for the agency. Employees are worried that pressing issues, such as resource allocation and health benefits, may go unaddressed as Bhattacharya juggles two important roles. This concern is heightened by recent decisions at the NIH to reduce funding for certain research areas, particularly those involving race and gender studies, which have stirred debates about the agency's commitment to inclusive science.

Jay Bhattacharya has gained notoriety for his vocal opposition to COVID-19 mitigation measures and has formed notable alliances, including with health secretary Robert F. Kennedy Jr. Under their leadership, the NIH has imposed restrictions on grants and faced criticism for hiring freezes that affect early-career scientists. This atmosphere of fiscal tightening and scarce resources has left many researchers anxious about their job security and the future of their projects, particularly in the wake of rising costs for essential services like health insurance.

With the recent focus on health benefits, NIH staff are particularly concerned about the affordability of health insurance for early-career scientists. Ian Morgan, a postdoctoral researcher at the NIH, brought attention to this issue during a recent meeting, reflecting broader anxieties shared by his colleagues. As costs rise and job insecurity looms, the dual pressures of Bhattacharya's new role may exacerbate existing challenges at the NIH, leaving staff worried about their ability to sustain livelihoods while advancing important research.